“Ed joins ALK with extensive experience in leading commercial growth, commercialising therapies, and advancing care for patients with allergic and immunologic conditions, combined with strong insights into the North American market which remains a key strategic focus area for ALK. We are very pleased to welcome Ed to ALK’s Executive Leadership Team where his pharma and market expertise will be greatly appreciated,” says President & CEO Peter Halling.

Edward Jordan

Edward Jordan, an American citizen, brings more than 30 years of biopharmaceutical experience, including roles at Merck (Schering-Plough), Teva Pharmaceuticals, and DBV Technologies, deep expertise in allergy and immunology, comprising work on Claritin, Clarinex, and Viaskin, as well as knowledge of the emerging food allergy market. With a strong track record in US commercial strategy, product launches, and market development, Edward Jordan has built therapeutic markets, established European and Scandinavian companies in the USA, and advanced therapies that improve patient outcomes. He holds an MBA from Southern New Hampshire University and dual bachelor’s degrees in finance and insurance from the University of Rhode Island.

“I’m honoured to join ALK at this pivotal moment. The momentum behind the Allergy+ strategy demonstrates ALK’s leadership and long-term commitment to allergy and associated conditions. I look forward to strengthening commercial execution to expand access and adoption across North America,” says Edward Jordan.